Table 1.

Association between TRPS-1 QS and other characteristics among 341 patients with stage I–III breast cancer (BC)

Characteristic	N (%)	TRPS-1 quick score (QS)			P*
		Maximum	Minimum	Median
Age
≥50 years	225 (66)	38.27	0.02	14.92	0.319
<50 years	116 (34)	33.07	0.01	16.56
Histology
Ductal	285 (83.6)	38.27	0.01	16.02	0.694
Lobular	29 (8.5)	35.23	0.33	12.35
Ductal and lobular	18 (5.3)	34.31	0.33	11.98
Other	9 (2.6)	19.98	.014	13.12
N stage
N0	158 (46.3)	36.42	0.02	18.00	0.001
N1, N2, N3	183 (53.7)	38.27	0.01	13.38
T stage
T1, T2	306 (89.7)	38.27	0.01	16.23	0.002
T3, T4	35 (10.3)	34.31	0.22	6.86
Clinical stage
I	81 (23.8)	36.42	0.24	19.69	0.000
II	217 (63.6)	38.27	0.01	13.85
III	43 (12.6)	34.31	0.22	10.45
Black nuclear grade
1 or 2	218 (63.9)	36.42	0.02	16.18	0.036
3	110 (32.3)	38.27	0.01	12.98
Missing	13 (3.8)
ER status
≥10% (positive)	226 (66.3)	38.27	0.10	15.52	0.681
<10% (negative)	95 (27.9)	35.95	0.01	18.60
Missing	20 (5.9)
ER QS
≥4	235 (68.9)	38.27	0.10	16.13	0.035
<4	101 (29.6)	34.83	0.01	13.12
Missing	5 (1.5)
PR status
≥10% (positive)	186(54.5)	36.42	0.14	16.18	0.275
<10% (negative)	132 (38.7)	38.27	0.01	15.32
Missing	23 (6.7)
HER2 status (IHC)
Positive (3+)	68 (19.9)	35.95	0.58	16.56	0.017
Negative (0–2+)	273 (80.1)	38.27	0.01	14.54
Subtype
HER2+	68 (19.9)	35.95	0.58	16.75	0.031
ER/PR+, HER2-	199 (58.4)	38.27	0.10	15.43
Triple negative	57 (16.7)	34.83	0.01	13.12
Missing	17 (5.0)
Adjuvant chemotherapy
No	153 (44.9)	34.83	0.14	15.22	0.509
Yes	183 (53.7)	38.27	0.01	15.89
Missing	5 (1.5)
Adjuvant radiation therapy
No	191 (56)	38.27	0.10	15.87	0.568
Yes	144 (42.2)	34.31	0.01	15.27
Missing	6 (1.8)
Adjuvant anti-hormonal therapy
No	157 (46)	34.83	0.01	15.61	0.713
Yes	177 (51.9)	38.27	0.02	15.43
Missing	7 (2.1)

*P values were determined by the Kruskal–Wallis test.